Targeting MAGL in brain support cells to help people with Alzheimer’s
Silencing of astrocytic MAGL as a therapy for Alzheimer’s disease
This project aims to lower MAGL activity in brain support cells (astrocytes) to reduce inflammation and protect memory in people with Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11457057 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers are using a virus-based gene tool to turn off the MAGL enzyme specifically in astrocytes, the brain's support cells, in laboratory models of Alzheimer's. They will look at whether this astrocyte-specific approach reduces brain inflammation, lessens buildup of Alzheimer’s-related proteins, and preserves memory-related function in those models. The team will compare targeted astrocyte silencing to broader MAGL suppression because past studies showed global inhibition can cause side effects. If the targeted approach works in the lab, it could form the basis for developing safer treatments for people with Alzheimer’s.
Who could benefit from this research
Good fit: People with Alzheimer’s disease—particularly those in earlier stages when inflammation-driven damage may be modifiable—would be the eventual candidates for this approach.
Not a fit: Patients with non-Alzheimer’s dementias or very advanced neurodegeneration may not benefit from this specific MAGL-targeting approach.
Why it matters
Potential benefit: If successful, this approach could reduce neuroinflammation and protect neurons, potentially slowing cognitive decline in Alzheimer's disease.
How similar studies have performed: Preclinical animal studies have shown that blocking MAGL can reduce Alzheimer's pathology, but global MAGL suppression caused adverse effects, so astrocyte-specific targeting is a newer strategy.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Chen, Chu — University of Texas Hlth Science Center
- Study coordinator: Chen, Chu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.